AbbVie (ABBV) and Genmab (GMAB) announced that their jointly developed bispecific antibody epcoritamab, marketed as Epkinly ...
Deep Origin docking software and molecular dynamics simulations pinpointed the lead compound from a 17-compound libraryComputational results ...
Genmab A/S(Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today provided clarification on the primary endpoints from the Phase 3 EPCORE® DLBCL-1 study evaluating monotherapy epcoritamab (DuoBody®-CD3xCD20), a ...
Diffuse large B-cell lymphoma (DLBCL) is a type of cancer that affects white blood cells called lymphocytes. There are two main types of lymphocytes: B-cell lymphocytes (B cells) and T-cell ...
Morning Overview on MSN
A drug hit its goal against an aggressive lymphoma in a late-stage trial
Patients with relapsed or refractory diffuse large B-cell lymphoma, one of the fastest-growing blood cancers, gained a new ...
In patients with previously untreated diffuse large B-cell lymphoma (DLBCL), polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) demonstrated sustained ...
Company Announcement Topline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated statistically significant and clinically meaningful improvement ...
BOSTON--(BUSINESS WIRE)--Novotech, the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel ...
Offering a Sense of Hope for Diffuse Large B-cell Lymphoma The Evolving Role of Bispecific Antibodies in Diffuse Large B-cell Lymphoma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results